Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
McKinsey
McKesson
Farmers Insurance
Medtronic
Federal Trade Commission
Cantor Fitzgerald
Accenture
Colorcon

Generated: June 25, 2018

DrugPatentWatch Database Preview

GALANTAMINE HYDROBROMIDE Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Galantamine Hydrobromide patents expire, and what generic alternatives are available?

Galantamine Hydrobromide is a drug marketed by Aurobindo Pharma Ltd, Barr, Impax Labs, Mylan, Sun Pharma Global, Watson Labs, West-ward Pharms Int, Actavis Elizabeth, Apotex Inc, Dr Reddys Labs Ltd, Sandoz, Teva Pharms, Yabao Pharm, and Zydus Pharms Usa Inc. and is included in nineteen NDAs.

The generic ingredient in GALANTAMINE HYDROBROMIDE is galantamine hydrobromide. There are fifteen drug master file entries for this compound. Twenty suppliers are listed for this compound. There are three tentative approvals for this compound. Additional details are available on the galantamine hydrobromide profile page.
Drug patent expirations by year for GALANTAMINE HYDROBROMIDE
Pharmacology for GALANTAMINE HYDROBROMIDE
Medical Subject Heading (MeSH) Categories for GALANTAMINE HYDROBROMIDE
Synonyms for GALANTAMINE HYDROBROMIDE
(+/-)-Galantamine hydrobromide
(+/-)-Galanthamine hydrobromide
(1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0^{1,12}.0^{6,17}]heptadeca-6(17),7,9,15-tetraen-14-ol hydrobromide
(4aS,6R,8aS)-3-methoxy-11-methyl-4a,5,9,10,11,12-hexahydro-6H-benzo[2,3]benzofuro[4,3-cd]azepin-6-ol hydrobromide
(4aS,6R,8aS)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6H-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol hydrobromide
(4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol Hydrobromide
1,2,3,4,6,7,7a,11c-Octahydro-9-methoxy-2-methyl-benzofuro(4,3,2-efg)(2)benzazocin-6-ol HBr
193146-85-9
1953-04-4
4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol hydrobromide
6H-Benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, hydrobromide (1:1), (4aR,6S,8aR)-rel-
6H-Benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, hydrobromide (1:1), (4aS,6R,8aS)-
6H-Benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, hydrobromide, (4aalpha,6beta,8ar*)-
6H-Benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, hydrobromide, (4aS,6R,8aS)-
6H-Benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-,hydrobromide, (4aS,6R,8aS)-
953G044
AC-469
AC1L3T0P
AC1Q23LL
AK146319
AKOS007930166
AKOS015960209
Ambap1953-04-4
anti-Alzheimer
AS-12155
BC200303
Benzofuro(4,3,2-efg)(2)benzazocin-6-ol, 1,2,3,4,6,7,7a,11c-octahydro-9-methoxy-2-methyl-, hydrobromide
C17H22BrNO3
CCG-38829
CG0027
CHEMBL1555
CPD000449267
CS-0378
D02173
DTXSID4052768
EINECS 217-780-5
FT-0082629
G0293
Galantamine hydrobromide (JAN/USAN)
Galantamine hydrobromide (racemic)
Galantamine hydrobromide [USAN:USP]
Galantamine hydrobromide [USAN]
Galantamine hydrobromide, (+/-)-
Galanthamine (hydrobromide)
Galanthamine HBr
Galanthamine hydrobromide
Galanthamine hydrobromide from Lycoris sp., >=94% (TLC)
Galanthamine hydrogen bromide
GALANTHAMINEHYDROBROMIDE
galanthaminhydrobromid(1:1)
GP-37267
HMS1569F18
HMS1921P21
HY-A0009
J10353
Jilcon hydrobromide
LS-185021
LS-35389
Lycoremine hydrobromide
MCULE-7403371703
MFCD00067672
MJ4PTD2VVW
MLS000758283
MLS001401401
MolPort-003-665-621
NC00061
Nivalin
Nivaline (C17 pharmaceutical)
Nivaline (pharmaceutical)
Prestwick_236
PubChem13654
QORVDGQLPPAFRS-XPSHAMGMSA-N
R-113675
Razadyne
Razadyne (TN)
Reminyl XL
Reminyl, 69353-21-5
s1339
SAM001246978
SCHEMBL177993
SMR000449267
SPECTRUM1501202
ST24047324
UNII-5N4SA4KQX9 component QORVDGQLPPAFRS-XPSHAMGMSA-N
UNII-MJ4PTD2VVW
W-5061
Z1558572528

US Patents and Regulatory Information for GALANTAMINE HYDROBROMIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sandoz GALANTAMINE HYDROBROMIDE galantamine hydrobromide TABLET;ORAL 077589-001 Jun 22, 2009 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Dr Reddys Labs Ltd GALANTAMINE HYDROBROMIDE galantamine hydrobromide TABLET;ORAL 077593-001 Sep 11, 2008 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
West-ward Pharms Int GALANTAMINE HYDROBROMIDE galantamine hydrobromide TABLET;ORAL 077608-003 Feb 11, 2009 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Teva Pharms GALANTAMINE HYDROBROMIDE galantamine hydrobromide TABLET;ORAL 077587-002 Jul 9, 2009 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Moodys
Baxter
Merck
UBS
Express Scripts
Queensland Health
Daiichi Sankyo
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.